PL370867A1 - Preparaty cysplatyny o zmniejszonej toksyczności i sposoby ich zastosowania - Google Patents

Preparaty cysplatyny o zmniejszonej toksyczności i sposoby ich zastosowania

Info

Publication number
PL370867A1
PL370867A1 PL02370867A PL37086702A PL370867A1 PL 370867 A1 PL370867 A1 PL 370867A1 PL 02370867 A PL02370867 A PL 02370867A PL 37086702 A PL37086702 A PL 37086702A PL 370867 A1 PL370867 A1 PL 370867A1
Authority
PL
Poland
Prior art keywords
methods
same
reduced toxicity
cisplatin formulations
cisplatin
Prior art date
Application number
PL02370867A
Other languages
English (en)
Inventor
Patrick Fogarty
Original Assignee
Tosk, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosk, Inc. filed Critical Tosk, Inc.
Publication of PL370867A1 publication Critical patent/PL370867A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02370867A 2001-09-24 2002-09-20 Preparaty cysplatyny o zmniejszonej toksyczności i sposoby ich zastosowania PL370867A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32456601P 2001-09-24 2001-09-24

Publications (1)

Publication Number Publication Date
PL370867A1 true PL370867A1 (pl) 2005-05-30

Family

ID=23264163

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370867A PL370867A1 (pl) 2001-09-24 2002-09-20 Preparaty cysplatyny o zmniejszonej toksyczności i sposoby ich zastosowania

Country Status (18)

Country Link
US (1) US20040258771A1 (pl)
EP (1) EP1435963A4 (pl)
JP (1) JP2005510471A (pl)
KR (1) KR20040048900A (pl)
CN (2) CN101062053A (pl)
AU (1) AU2002334595B2 (pl)
BR (1) BR0212744A (pl)
CA (1) CA2461219A1 (pl)
EA (1) EA007481B1 (pl)
HU (1) HUP0500642A2 (pl)
IL (1) IL160960A0 (pl)
MX (1) MXPA04002707A (pl)
NO (1) NO20041484L (pl)
NZ (1) NZ531936A (pl)
PL (1) PL370867A1 (pl)
SK (1) SK1472004A3 (pl)
WO (1) WO2003026570A2 (pl)
ZA (1) ZA200402229B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815833B2 (en) 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
CN103044338B (zh) * 2012-12-12 2016-08-03 天津医科大学总医院 miR-21小分子抑制剂及应用
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
PE20191653A1 (es) * 2016-11-11 2019-11-07 Univ Western Health Sciences Metodos para tratar carcinomas uroteliales del tracto superior
CN112574255B (zh) * 2019-09-27 2024-05-10 中国科学院上海有机化学研究所 一类基于有机胂的cdk抑制剂及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5366723A (en) * 1993-03-05 1994-11-22 Istvan Tulok Method of alleviating toxicity originating from treatment with anticancer platinum compounds
JPH06321792A (ja) * 1993-05-18 1994-11-22 Tsumura & Co 副作用軽減剤
US5646011A (en) * 1994-04-08 1997-07-08 Yokoyama; Shiro Cisplatin resistance gene and uses therefor
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6077545A (en) * 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
EP0930877B1 (en) * 1996-10-03 2006-04-19 Southern Illinois University D-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
CN1104378C (zh) * 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US6030783A (en) * 1997-01-31 2000-02-29 Massachusetts Institute Of Technology Photo-potentiation of cisplatin chemotherapy
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
WO2000023074A1 (en) * 1998-10-22 2000-04-27 Binex Co., Ltd. Pharmaceutical composition containing decursin
US6130245A (en) * 1998-10-26 2000-10-10 Unitech Pharmaceuticals, Inc. Dinuclear platinum complexes as cisplatin analogs for cancer treatment
NZ522767A (en) * 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
JP2005510471A (ja) 2005-04-21
CA2461219A1 (en) 2003-04-03
HUP0500642A2 (hu) 2005-11-28
CN101062053A (zh) 2007-10-31
NZ531936A (en) 2006-10-27
IL160960A0 (en) 2004-08-31
EP1435963A2 (en) 2004-07-14
EA007481B1 (ru) 2006-10-27
US20040258771A1 (en) 2004-12-23
SK1472004A3 (en) 2004-10-05
EA200400348A1 (ru) 2005-04-28
ZA200402229B (en) 2005-03-22
CN1589149A (zh) 2005-03-02
EP1435963A4 (en) 2005-10-26
WO2003026570A2 (en) 2003-04-03
NO20041484L (no) 2004-04-13
WO2003026570A3 (en) 2004-01-22
KR20040048900A (ko) 2004-06-10
BR0212744A (pt) 2005-10-25
MXPA04002707A (es) 2005-06-06
AU2002334595B2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
TW595857U (en) 091219345
AU2002357119A8 (en) Mitocidal compositions and methods
GB2406009B (en) Amplifier
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
IL158099A0 (en) Amplifier
AU2002357748A8 (en) Osteopontin-related compositions and methods
ZA200206779B (en) Solid formulation.
GB0126889D0 (en) Compounds and their uses
IL146740A0 (en) Locking amplifier
IL160960A0 (en) Reduced toxicity cisplatin formulations and methods for using the same
GB0101784D0 (en) Amplifier
GB0125492D0 (en) Formulation
PL363372A1 (pl) Pirolokarboksyamidy do stosowania jako fungicydy
GB0101992D0 (en) Pesticidal formulation
AU2002359869A8 (en) Pak5-related compositions and methods
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB2381977B (en) Amplifiers
GB0116619D0 (en) Formulation
GB0115893D0 (en) Formulations
GB0120882D0 (en) Amplifier
GB0110854D0 (en) Amplifier
GB0116458D0 (en) Amplifier
GB0112497D0 (en) Formulation
EG23003A (en) Synergistic formulations

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)